Stay updated on Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial page.

Latest updates to the Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov footer now lists revision v3.8.0 instead of v3.7.2. The study record remains inaccessible behind a 403 Forbidden page.SummaryDifference0.2%

- Check7 days agoChange DetectedA sitewide NIH notice announces a terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check14 days agoChange DetectedThe site revision label in the footer changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check21 days agoChange DetectedThe footer’s displayed site revision changes from v3.7.0 to v3.7.1; the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study details and navigation with a standard error page; the previously visible study information is no longer accessible on this page.SummaryDifference18%

- Check63 days agoChange DetectedVersion label updated from v3.6.5 to v3.6.6, indicating a small site maintenance update. This change does not alter the study details or user-facing functionality.SummaryDifference0.1%

Stay in the know with updates to Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial page.